LKB1 inhibits HPV-associated cancer progression by targeting cellular metabolism

Oncogene

Volumn 36, Issue 9, 2017, Pages 1245-1255

  Zeng, Q ^a,b   Chen, J ^b   Li, Y ^b   Werle, K D ^b   Zhao, R X ^b   Quan, C S ^a   Wang, Y S ^a   Zhai, Y X ^a   Wang, J W ^a   Youssef, M ^b   Cui, R ^c   Liang, J ^d   Genovese, N ^e   Chow, L T ^e   Li, Y L ^a   Xu, Z X ^a,b  

^a Basic Medical College   (China)

^b Heerskink School of Medicine   (United States)

^c BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; GLUCOSE; HEXOKINASE II; LACTIC ACID; PHOSPHOTRANSFERASE; PROTEIN KINASE LKB1; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG; E6 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 16; HEXOKINASE; ONCOGENE PROTEIN E7, HUMAN PAPILLOMAVIRUS TYPE 16; ONCOPROTEIN; PROTEIN E7; PROTEIN SERINE THREONINE KINASE; REPRESSOR PROTEIN; STK11 PROTEIN, HUMAN; TUMOR MARKER;

AEROBIC GLYCOLYSIS; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CANCER GROWTH; CARCINOGENESIS; CELL AGING; CELL GROWTH; CELL METABOLISM; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE ASSOCIATION; ECTOPIC EXPRESSION; EMBRYO; ENZYME PHOSPHORYLATION; FEMALE; FIBROBLAST; GLUCOSE INTAKE; GLUCOSE METABOLISM; HELA CELL LINE; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN TISSUE; IMMUNOBLOTTING; IN VITRO STUDY; IN VIVO STUDY; LUNG METASTASIS; MAJOR CLINICAL STUDY; MOUSE; NONHUMAN; ONCOGENE C MYC; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; UTERINE CERVIX CANCER; WESTERN BLOTTING; ANIMAL; APOPTOSIS; C57BL MOUSE; CANCER STAGING; CASE CONTROL STUDY; CELL TRANSFORMATION; COMPARATIVE STUDY; FOLLOW UP; GENETICS; GLYCOLYSIS; METABOLISM; PAPILLOMAVIRUS INFECTION; PATHOLOGY; PHYSIOLOGY; PROGNOSIS; TUMOR CELL CULTURE; UTERINE CERVIX TUMOR; VIROLOGY;

ANIMALS; APOPTOSIS; BIOMARKERS, TUMOR; CASE-CONTROL STUDIES; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; FEMALE; FOLLOW-UP STUDIES; GLUCOSE; GLYCOLYSIS; HEXOKINASE; HUMAN PAPILLOMAVIRUS 16; HUMANS; MICE; MICE, INBRED C57BL; NEOPLASM STAGING; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS E7 PROTEINS; PAPILLOMAVIRUS INFECTIONS; PROGNOSIS; PROTEIN-SERINE-THREONINE KINASES; REPRESSOR PROTEINS; TUMOR CELLS, CULTURED; UTERINE CERVICAL NEOPLASMS;

EID: 84983523249     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2016.290     Document Type: Article

References (56)

1. Arbyn M, Castellsagué X, de Sanjosé S, Bruni L, Saraiya M, Bray F et al. Worldwide burden of cervical cancer in 2008. Ann Oncol 2011; 22: 2675-2686.
2. zur Hausen H. Papillomaviruses in the causation of human cancers-a brief historical account. Virology 2009; 384: 260-265.
3. Scheffner M, Munger K, Byrne JC, Howley PM. The state of the p53 and retino-blastoma genes in human cervical carcinoma cell lines. Proc Natl Acad Sci USA 1991; 88: 5523-5527.
4. Galloway DA, Laimins LA. Human papillomaviruses: shared and distinct pathways for pathogenesis. Curr Opin Virol 2015; 14: 87-92.
5. Psyrri A, DiMaio D. Human papillomavirus in cervical and head-and-neck cancer. Nat Clin Pract Oncol. 2008; 5: 24-31.
6. Moody CA, Laimins LA. Human papillomavirus oncoproteins: pathways to transformation. Nat Rev Cancer 2010; 10: 550-560.
7. Hemminki A, Markie D, Tomlinson I, Avizienyte E, Roth S, Loukola A et al. A serine/threonine kinase gene defective in Peutz-Jeghers syndrome. Nature 1998; 391: 184-187.
8. Hardie DG, Alessi DR. LKB1 and AMPK and the cancer-metabolism link-ten years after. BMC Biol 2013; 11: 36.
9. Shackelford DB, Abt E, Gerken L, Vasquez DS, Seki A, Leblanc M et al. LKB1 inactivation dictates therapeutic response of non-small cell lung cancer to the metabolism drug phenformin. Cancer Cell 2013; 23: 143-158.
10. Ji H, Ramsey MR, Hayes DN, Fan C, McNamara K, Kozlowski P et al. LKB1 modulates lung cancer differentiation and metastasis. Nature 2007; 448: 807-810.
11. Wingo SN, Gallardo TD, Akbay EA, Liang MC, Contreras CM, Boren T et al. Somatic LKB1 mutations promote cervical cancer progression. PLoS One 2009; 4: e5137.
12. Pavlova NN, Thompson CB. The emerging hallmarks of cancer metabolism. Cell Metab 2016; 23: 27-47.
13. Boroughs LK, DeBerardinis RJ. Metabolic pathways promoting cancer cell survival and growth. Nat Cell Biol 2015; 17: 351-359.
14. Ayre HA, Goldberg DM. Enzymes of the human cervix uteri. Comparison of dehydrogenases of lactate, isocitrate, and phosphogluconate in malignant and non-malignant tissue samples. Br J Cancer 1966; 20: 743-750.
15. Mazurek S, Zwerschke W, Jansen-Durr P, Eigenbrodt E. Effects of the human papilloma virus HPV-16 E7 oncoprotein on glycolysis and glutaminolysis: role of pyruvate kinase type M2 and the glycolytic-enzyme complex. Biochem J 2001; 356: 247-256.
16. Zwerschke W, Mazurek S, Masssini P, Banks L, Eigenbrod E, Jansen-Dürr P et al. Modulation of type M2 pyruvate kinase activity by the human papillomavirus type 16 E7 oncoprotein. Proc Natl Acad Sci USA 1999; 96: 1291-1296.
17. Walenta S, Wetterling M, Lehrke M, Schwickert G, Sundfør K, Rofstad EK et al. High lactate levels predict likelihood of metastases, tumor recurrence, and restricted patient survival in human cervical cancers. Cancer Res 2000; 60: 916-921.
18. Salama R, Sadaie M, Hoare M, Narita M. Cellular senescence and its effector programs. Genes Dev 2014; 28: 99-114.
19. Dörr JR, Yu Y, Milanovic M, Beuster G, Zasada C, Däbritz JH et al. Synthetic lethal metabolic targeting of cellular senescence in cancer therapy. Nature 2013; 501: 421-425.
20. Zeng Q, Zhao RX, Chen J, Li Y, Li XD, Liu XL et al. O-linked GlcNAcylation elevated by HPV E6 mediates viral oncogenesis. Proc Natl Acad Sci USA 2016; e-pub ahead of print 1 August 2016; doi:10.1073/pnas.1606801113.
21. Bardeesy N, Sinha M, Hezel AF, Signoretti S, Hathaway NA, Sharpless NE et al. Loss of the Lkb1 tumour suppressor provokes intestinal polyposis but resistance to transformation. Nature 2002; 419: 162-167.
22. Ji H, Chang EY, Lin KY, Kurman RJ, Pardoll DM, Wu TC et al. Antigen-specific immunotherapy for murine lung metastatic tumors expressing human papillo-mavirus type 16 E7 oncoprotein. Int J Cancer 1998; 78: 41-45.
23. McLaughlin-Drubin ME, Munger K. Oncogenic activities of human papilloma-viruses. Virus Res 2009; 143: 195-208.
24. Xiao X, He Q, Lu C, Werle KD, Zhao RX, Chen J et al. Metformin impairs the growth of liver kinase B1-intact cervical cancer cells. Gynecol Oncol 2012; 127: 249-255.
25. McCabe MT, Powell DR, Zhou W, Vertino PM. Homozygous deletion of the STK11/LKB1 locus and the generation of novel fusion transcripts in cervical cancer cells. Cancer Genet Cytogenet 2010; 197: 130-141.
26. Mack HI, Munger K. The LKB1 tumor suppressor differentially affects anchorage independent growth of HPV positive cervical cancer cell lines. Virology 2013; 446: 9-16.
27. Lu Z, Hu X, Li Y, Zheng L, Zhou Y, Jiang H et al. Human papillomavirus 16 E6 oncoprotein interferences with insulin signaling pathway by binding to tuberin. J Biol Chem 2004; 279: 35664-35670.
28. Zheng L, Ding H, Lu Z, Li Y, Pan Y, Ning T et al. E3 ubiquitin ligase E6AP-mediated TSC2 turnover in the presence and absence of HPV16 E6. Genes Cells 2008; 13: 285-294.
29. Spangle JM, Münger K. The human papillomavirus type 16 E6 oncoprotein activates mTORC1 signaling and increases protein synthesis. J Virol 2010; 84: 9398-9407.
30. Patra KC, Wang Q, Bhaskar PT, Miller L, Wang Z, Wheaton W et al. Hexokinase 2 is required for tumor initiation and maintenance and its systemic deletion is therapeutic in mouse models of cancer. Cancer Cell 2013; 24: 213-228.
31. Roberts DJ, Miyamoto S. Hexokinase II integrates energy metabolism and cellular protection: Akting on mitochondria and TORCing to autophagy. Cell Death Differ 2015; 22: 248-257.
32. Balko JM, Cook RS, Vaught DB, Kuba MG, Miller TW, Bhola NE et al. Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance. Nat Med 2012; 18: 1052-1059.
33. Mathupala SP, Rempel A, Pedersen PL. Glucose catabolism in cancer cells: identification and characterization of a marked activation response of the type II hexokinase gene to hypoxic conditions. J Biol Chem 2001; 276: 43407-43412.
34. Partanen JI, Nieminen AI, Mäkelä TP, Klefstrom J. Suppression of oncogenic properties of c-Myc by LKB1-controlled epithelial organization. Proc Natl Acad Sci USA 2007; 104: 14694-14699.
35. Gabay M, Li Y, Felsher DW. MYC activation is a hallmark of cancer initiation and maintenance. Cold Spring Harb Perspect Med 2014; 4: a014241.
36. Altman BJ, Hsieh AL, Sengupta A, Krishnanaiah S, Stine ZE, Walton ZE et al. MYC disrupts the Circadian clock and metabolism in cancer cells. Cell Metab 2015; 22: 1009-1019.
37. Dendele B, Tekpli X, Sergent O, Dimanche-Boitrel MT, Holme JA, Huc L et al. Identification of the couple GSK3alpha/c-MYC as a new regulator of hexokinase II in benzo[a]pyrene-induced apoptosis. Toxicol In Vitro 2012; 26: 94-101.
38. Ojesina AI, Lichtenstein L, Freeman SS, Pedamallu CS, Imaz-Rosshandler I, Pugh TJ et al. Landscape of genomic alterations in cervical carcinomas. Nature 2014; 506: 371-375.
39. Cairns RA, Harris IS, Mak TW. Regulation of cancer cell metabolism. Nat Rev Cancer 2011; 11: 85-95.
40. Cheung EC, Ludwig RL, Vousden KH. Mitochondrial localization of TIGAR under hypoxia stimulates HK2 and lowers ROS and cell death. Proc Natl Acad Sci USA 2012; 109: 20491-20496.
41. Wolf A, Agnihotri S, Micallef J, Mukherjee J, Sabha N, Cairns R et al. Hexokinase 2 is a key mediator of aerobic glycolysis and promotes tumor growth in human glioblastoma multiforme. J Exp Med 2011; 208: 313-326.
42. Wu R, Wyatt E, Chawla K, Tran M, Ghanefar M, Laakso M et al. Hexokinas II knockdown results in exaggerated cardiac hypertrophy via increased ROS production. EMBO Mol Med 2012; 4: 633-646.
43. Anflous-Pharayra K, Cai ZJ, Craigen WJ. VDAC1 serves as a mitochondrial binding site for hexokinase in oxidative muscles. Biochim Biophys Acta 2007; 1767: 136-142.
44. John S, Weiss JN, Ribalet B. Subcellular localization of hexokinases I and II directs the metabolic fate of glucose. PLoS One 2011; 6: e17674.
45. Andrade-Vieira R, Xu Z, Colp P, Marignani PA. Loss of lkb1 expression reduces the latency of ErbB2-mediated mammary gland tumorigenesis, promoting changes in metabolic pathways. PLoS One 2013; 8: e56567.
46. Kaplon J, Zheng L, Meissl K, Chaneton B, Selivanov VA, Mackay G et al. A key role for mitochondrial gatekeeper pyruvate dehydrogenase inoncogene-induced senescence. Nature 2013; 498: 109-112.
47. Faubert B, Vincent EE, Griss T, Samborska B, Izreig S, Svensson RU et al. Loss of the tumor suppressor LKB1 promotes metabolic reprogramming of cancer cells via HIF-1α. Proc Natl Acad Sci USA 2014; 111: 2554-2559.
48. Mohseni M, Sun J, Lau A, Curtis S, Goldsmith J, Fox VL et al. A genetic screen identifies an LKB1-MARK signalling axis controlling the Hippo-YAP pathway. Nat Cell Biol 2014; 16: 108-117.
49. Liu W, Monahan KB, Pfefferle AD, Shimamura T, Sorrentino J, Chan KT et al. LKB1/STK11 inactivation leads to expansion of a prometastatic tumor subpopulation in melanoma. Cancer Cell 2012; 21: 751-764.
50. Yuan P, Ito K, Perez-Lorenzo R, Del Guzzo C, Lee JH, Shen CH et al. Phenformin enhances the therapeutic benefit of BRAF(V600E) inhibition in melanoma. Proc Natl Acad Sci USA 2013; 110: 18226-18231.
51. Carretero J, Shimamura T, Rikova K, Jackson AL, Wilkerson MD, Borgman CL et al. Integrative genomic and proteomic analyses identify targets for Lkb1-deficient metastatic lung tumors. Cancer Cell 2010; 17: 547-559.
52. Shackelford DB, Vasquez DS, Corbeil J, Wu S, Leblanc M, Wu CL et al. mTOR and HIF-1alpha-mediated tumor metabolism in an LKB1 mouse model of Peutz-Jeghers syndrome. Proc Natl Acad Sci USA 2009; 106: 11137-11142.
53. Hardie DG. AMP-activated protein kinase: a key regulator of energy balance with many roles in human disease. J Intern Med 2014; 276: 543-559.
54. Fauber B, Vincent EE, Griss T, Samborska B, Izreig S, Svensson RU et al. Loss of the tumor suppressor LKB1 promotes metabolic reprogramming of cancer cells via HIF-1α. Proc Natl Acad Sci USA 2014; 111: 2554-2559.
55. Dupuy F, Griss T, Blagih J, Bridon G, Avizonis D, Ling C et al. LKB1 is a central regulator of tumor initiation and pro-growth metabolism in ErbB2-mediated breast cancer. Cancer Metab 2013; 1: 18.
56. Xu HG, Zhai YX, Chen J, Lu Y, Wang JW, Quan CS et al. LKB1 reduces ROS-mediated cell damage via activation of p38. Oncogene 2015; 34: 3848-3859.